Company Information
Industry 制造业
Company Introduction 公司于2003年8月成立,是一家专注于高端外科手术吻合器研发创新和生产销售的高新技术企业。通过近17年来不断自主研发创新,公司已拥有管型吻合器、腔镜吻合器、线型切割吻合器、荷包吻合器和线型缝合吻合器5大类产品,应用范围涵盖心胸外科、胃肠外科、肝胆脾胰外科、普外科、泌尿外科等手术领域。 公司坚持“自主创新,研发先行,专利布局”的方式,研发具有自主知识产权的产品,研发创新成果丰硕,在境内外实施了相应的专利布局。截至2019年底,公司拥有境内外专利380项,其中发明专利228项,覆盖中国、欧洲、美国、日本等国家和地区,有效突破了美国医疗器械巨头在该领域垄断多年的知识产权壁垒,成为国内高端外科手术吻合器出口的领先企业。 公司始终坚持高质量研发投入,包括人才引进、专利布局、研发实验设施完善等,不断提高创新研发能力,持续输出技术领先、顺应市场发展趋势的新产品。公司严格按照相关法规标准的要求,建立了完整、全面的质量管理体系,涵盖了从产品研发到生产、销售及售后全过程的质量管理,也获得了欧盟、巴西和韩国等相关组织机构的认证。 公司将持续努力创造更具临床价值、更高品质的吻合器产品,致力于成为高端外科手术吻合器的创新和生产基地。
Main Business 高端外科手术吻合器研发创新和生产销售
Legal Representative 陈望宇
Top Executives
董事长:陈望宇
董事:杨彩红,陈望东,田国玉
独立董事:金文龙,陆志安,范明
Top 5 Shareholder
Shareholder name Nature Holding Date
陈望宇流通A股25.85%31/03/2024
陈望东流通A股25.79%31/03/2024
Inspire Surgical Limited流通A股4.27%31/03/2024
刘伟流通A股2.32%31/03/2024
昆山分享股权投资企业(有限合伙)流通A股1.87%31/03/2024
Company Secretary 田国玉
Solicitors 国浩律师(上海)事务所
Auditors 中天运会计师事务所(特殊普通合伙)
Tel No 0512-68601988;0512-62991907
Fax No 0512-62991902
Website www.touchstonesurgical.com
Email tsbs@touchstone.hk
Company Address
Register: 江苏省苏州工业园区东平街278号
Office: 江苏省苏州工业园区东平街278号
Listing Date 28/09/2020
Shares Capital
Shares Capital: 81,155,600
Total A Share: 81,155,600
Listed A Share: 81,155,600
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.600
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 7.042
Market Capitalization(RMB) 1.331B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.